Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months
Objectives. Bisphosphonates related osteonecrosis of the jaw (BRONJ) is a pathological condition characterized by bone exposure or latent infection in patients treated with the drug. The aim of the study is to monitor the BRONJ level of risk health in patients with cancer, according to a preventive...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Dentistry |
| Online Access: | http://dx.doi.org/10.1155/2014/475859 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562680878071808 |
|---|---|
| author | Scilla Sparabombe Lucia Vitali Alessandra Nori Ricarda Sara Berlin Marta Mazur Giovanna Orsini Angelo Putignano |
| author_facet | Scilla Sparabombe Lucia Vitali Alessandra Nori Ricarda Sara Berlin Marta Mazur Giovanna Orsini Angelo Putignano |
| author_sort | Scilla Sparabombe |
| collection | DOAJ |
| description | Objectives. Bisphosphonates related osteonecrosis of the jaw (BRONJ) is a pathological condition characterized by bone exposure or latent infection in patients treated with the drug. The aim of the study is to monitor the BRONJ level of risk health in patients with cancer, according to a preventive clinical protocol, which is firstly aimed at reducing risk factors such as the periodontal infections.
Materials and Methods. 10 patients participated in the protocol and were evaluated at baseline and after 3 and 18 months of treatment with bisphosphonates, through full mouth plaque and bleeding scores (FMPS and FMBS), clinical attachment level (CAL) measurement, and the occurrence of osteonecrosis. Results. The mean plaque and bleeding were reduced and the CAL has not shown significant changes and in no cases was there manifestation of BRONJ. Conclusion. The protocol proved crucial for the maintenance of good oral health conditions by eliminating the risk of BRONJ during the observation period. |
| format | Article |
| id | doaj-art-8d9660ab7f3e4606abf5501f6a4feac1 |
| institution | Kabale University |
| issn | 1687-8728 1687-8736 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Dentistry |
| spelling | doaj-art-8d9660ab7f3e4606abf5501f6a4feac12025-02-03T01:22:07ZengWileyInternational Journal of Dentistry1687-87281687-87362014-01-01201410.1155/2014/475859475859Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 MonthsScilla Sparabombe0Lucia Vitali1Alessandra Nori2Ricarda Sara Berlin3Marta Mazur4Giovanna Orsini5Angelo Putignano6Department of Clinical Sciences and Stomatology, Faculty of Medicine, Polytechnic University of Marche, Palace “Murri”, Floor No. 3, Via Tronto 10, 60126 Ancona, ItalyDepartment of Clinical Sciences and Stomatology, Faculty of Medicine, Polytechnic University of Marche, Palace “Murri”, Floor No. 3, Via Tronto 10, 60126 Ancona, ItalySpecial and Surgical Stomatology Department, “Ospedali Riuniti” Hospital of Ancona, Via Conca 2, 60126 Ancona, ItalySpecial and Surgical Stomatology Department, “Ospedali Riuniti” Hospital of Ancona, Via Conca 2, 60126 Ancona, ItalyStomatology and Maxillofacial Science Department, University of Rome “La Sapienza”, ItalyDepartment of Clinical Sciences and Stomatology, Faculty of Medicine, Polytechnic University of Marche, Palace “Murri”, Floor No. 3, Via Tronto 10, 60126 Ancona, ItalyDepartment of Clinical Sciences and Stomatology, Faculty of Medicine, Polytechnic University of Marche, Palace “Murri”, Floor No. 3, Via Tronto 10, 60126 Ancona, ItalyObjectives. Bisphosphonates related osteonecrosis of the jaw (BRONJ) is a pathological condition characterized by bone exposure or latent infection in patients treated with the drug. The aim of the study is to monitor the BRONJ level of risk health in patients with cancer, according to a preventive clinical protocol, which is firstly aimed at reducing risk factors such as the periodontal infections. Materials and Methods. 10 patients participated in the protocol and were evaluated at baseline and after 3 and 18 months of treatment with bisphosphonates, through full mouth plaque and bleeding scores (FMPS and FMBS), clinical attachment level (CAL) measurement, and the occurrence of osteonecrosis. Results. The mean plaque and bleeding were reduced and the CAL has not shown significant changes and in no cases was there manifestation of BRONJ. Conclusion. The protocol proved crucial for the maintenance of good oral health conditions by eliminating the risk of BRONJ during the observation period.http://dx.doi.org/10.1155/2014/475859 |
| spellingShingle | Scilla Sparabombe Lucia Vitali Alessandra Nori Ricarda Sara Berlin Marta Mazur Giovanna Orsini Angelo Putignano Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months International Journal of Dentistry |
| title | Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months |
| title_full | Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months |
| title_fullStr | Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months |
| title_full_unstemmed | Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months |
| title_short | Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months |
| title_sort | risk assessment of bronj in oncologic patients treated with bisphosphonates follow up to 18 months |
| url | http://dx.doi.org/10.1155/2014/475859 |
| work_keys_str_mv | AT scillasparabombe riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months AT luciavitali riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months AT alessandranori riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months AT ricardasaraberlin riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months AT martamazur riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months AT giovannaorsini riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months AT angeloputignano riskassessmentofbronjinoncologicpatientstreatedwithbisphosphonatesfollowupto18months |